NICE Publishes Final Recommendation for Novartis’ Piqray and Gilead’s Trodelvy to Treat Breast Cancer
Shots:
- NICE has issued final draft guidance recommending Novartis’ Piqray (alpelisib) on the NHS for HR+, HER2-, PIK3CA-mutated LA, or metastatic breast cancer that has grown after treatment with combined hormonal therapy and a cancer growth inhibitor
- NICE also recommended Gilead’s Trodelvy (sacituzumab govitecan) used for LA or metastatic TNBC that can’t be treated with surgery, after ≥2 lines of systemic therapies. Trodelvy will be available to patients in Wales and Northern Ireland
- Since 2018, NICE has also maintained a 100% approval rate for breast cancer & reported that Piqray and Trodelvy are effective additional options to provide a better QoL for advanced breast cancer patients
Ref: NICE | Image: NICE
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
